Parkinson’s disease is a synucleinopathy, characterized by the misfolding, spread, and aggregation of α-synuclein. Researchers suggest that lipid metabolism in the brain may play a crucial role in α-synuclein-induced neuronal dysfunction and death. Exploring this understudied topic could potentially lead to innovative therapeutic strategies.
Aggregation of α-synuclein is implicated in neurodegenerative diseases like Parkinson’s disease, dementia with Lewy Bodies, and multiple system atrophy. The interaction between α-synuclein and lipid metabolism is increasingly recognized, with alterations in membrane lipid composition influencing α-synuclein aggregation. Genetic factors affecting lipid metabolism have been linked to PD and DLB risk, emphasizing the intricate relationship between lipid composition and α-synuclein aggregation. Further research is needed to elucidate the impact of lipid changes on α-synuclein-related neurodegeneration.
For more information, refer to the link: https://doi.org/10.3389/fmolb.2024.1455817
